Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Y-90 cT84.66, Gemcitabine, and FUdR for Metastatic Colorectal Carcinoma to the Liver
NCT00645710Phase 2Completed
- Sponsor
- City of Hope
- Start
- Jun 2005
- Primary completion
- Feb 2018
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 2 trial of yttrium-90-DTPA-cT84.66, gemcitabine, floxuridine in colorectal cancer (CRC), liver metastases, sponsored by City of Hope. Started Jun 2005; status: completed.
02
Drugs
yttrium-90-DTPA-cT84.66gemcitabinefloxuridine
03
Conditions
colorectal cancer (CRC)liver metastases
Beyond the preview
Go deeper on NCT00645710.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00645710.